These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
66. Sensorineural hearing loss associated with intrathecal vancomycin. Klibanov OM; Filicko JE; DeSimone JA; Tice DS Ann Pharmacother; 2003 Jan; 37(1):61-5. PubMed ID: 12503934 [TBL] [Abstract][Full Text] [Related]
67. Methadone associated long term hearing loss and nephrotoxicity; a case report and literature review. Ghasemi S; Izadpanahi S; Yaghoubi MA; Brent J; Mehrpour O Subst Abuse Treat Prev Policy; 2019 Nov; 14(1):48. PubMed ID: 31694678 [TBL] [Abstract][Full Text] [Related]
68. An open assessment of tenoxicam (Tilcotil) in the treatment of acute gout in general practice. Waterworth RF; Waterworth SM N Z Med J; 1987 Dec; 100(837):744-5. PubMed ID: 3502545 [TBL] [Abstract][Full Text] [Related]
74. Reversible sensorineural hearing loss after renal transplant immunosuppression with OKT3 (muromonab-CD3). Hartnick CJ; Cohen AF; Smith RV Ann Otol Rhinol Laryngol; 1997 Aug; 106(8):640-2. PubMed ID: 9270425 [TBL] [Abstract][Full Text] [Related]
75. Treating gout in the presence of cardiac failure. Jolobe O Practitioner; 1994 Jun; 238(1539):489-90. PubMed ID: 8208665 [No Abstract] [Full Text] [Related]
76. Risks and benefits of drugs used in the management and prevention of gout. Conaghan PG; Day RO Drug Saf; 1994 Oct; 11(4):252-8. PubMed ID: 7848545 [TBL] [Abstract][Full Text] [Related]
77. Consumption of non-steroidal anti-inflammatory drugs and the development of functional renal impairment in elderly subjects. Results of a case-control study. Henry D; Page J; Whyte I; Nanra R; Hall C Br J Clin Pharmacol; 1997 Jul; 44(1):85-90. PubMed ID: 9241101 [TBL] [Abstract][Full Text] [Related]
78. Summaries for Patients. Oral Prednisolone in the Treatment of Acute Gout. Ann Intern Med; 2016 Apr; 164(7):. PubMed ID: 26902107 [No Abstract] [Full Text] [Related]
79. Etanercept therapy for immune-mediated cochleovestibular disorders: a multi-center, open-label, pilot study. Matteson EL; Choi HK; Poe DS; Wise C; Lowe VJ; McDonald TJ; Rahman MU Arthritis Rheum; 2005 Jun; 53(3):337-42. PubMed ID: 15934127 [TBL] [Abstract][Full Text] [Related]
80. Anti-inflammatory effect and low ulcerogenic activity of etodolac, a cyclooxygenase-2 selective non-steroidal anti-inflammatory drug, on adjuvant-induced arthritis in rats. Tachibana M; Inoue N; Yoshida E; Matsui M; Ukai Y; Yano J Pharmacology; 2003 Jun; 68(2):96-104. PubMed ID: 12711837 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]